Hudson Bay Capital Management
ROIV icon

Hudson Bay Capital Management’s Roivant Sciences ROIV Stock Holding History

Hudson Bay Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30,000
Closed -$240K – 973
2022
Q4 		$240K Buy
+30,000
New +$167K ﹤0.01% 742

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Hudson Bay Capital Management's ROIV Position: Q2 2026 in Review

Hudson Bay Capital Management opened a new position in Roivant Sciences (ROIV) in Q2 2026: 34,870 shares worth $1.23M. The stake represents ﹤0.01% of the portfolio and ranks #893 among its holdings.

500 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Hudson Bay Capital Management held 34,870 shares of Roivant Sciences worth $1.23M as of Q2 2026.
  • Roivant Sciences was a new Hudson Bay Capital Management position in Q2 2026.
  • Roivant Sciences made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #893 holding.
  • 500 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.